Literature DB >> 10870093

Pharmacokinetics and tissue distribution of olanzapine in rats.

M Aravagiri1, Y Teper, S R Marder.   

Abstract

The single dose pharmacokinetics of olanzapine in rats, following an oral dose and its distribution in the brain and other tissues after repeated oral and intra-peritoneal (i.p.) administration, were studied. Olanzapine in plasma, brain, liver, lung, kidney, spleen and fat was assayed at predose, 0.25, 0.5, 1, 2, 5, 12, 24, 36, 48 h postoral dose of 6 mg/kg and after daily oral and i.p. doses of 0.25, 1, 3, and 6 mg/kg/day of olanzapine for 15 consecutive days by a sensitive and specific HPLC method with electrochemical detection. Olanzapine was readily absorbed and distributed in plasma and tissues as the peak concentrations were reached within approximately 45 min after the oral dose. The terminal half-life of olanzapine in plasma was 2.5 h and in tissues it ranged from 3 to 5.2 h. The area under the concentration-time curve (AUC(last)) was lowest in plasma and largest in liver and lung. The AUC(last) of olanzapine was eight times larger in brain and three to 32 times larger in other tissues than that in plasma. After repeated oral doses, the plasma and tissue concentrations of olanzapine were generally higher than those after repeated i.p. doses. The liver and spleen had the highest concentrations after oral and i.p doses, respectively. In both cases, the tissue concentrations were four- to 46-fold higher than that in plasma and correlated with administered doses. Likewise, plasma concentrations strongly correlated with the simultaneous brain and tissue concentrations (r(2)>0.908, p<0.0001). On average, the brain levels were 6.3-13.1 and 5.4-17.6 times higher than the corresponding plasma level after oral and i.p. doses, respectively. The tissue to plasma level ratio of olanzapine was higher in other tissues. The data indicated that olanzapine is rapidly absorbed and widely distributed in the tissues of rats after oral and i.p. administration. The plasma concentration appears to predict the simultaneous concentration in brain and other tissues. There was no marked localized accumulation of olanzapine in any of the regions of the rat brain. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10870093     DOI: 10.1002/1099-081x(199911)20:8<369::aid-bdd200>3.0.co;2-6

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  50 in total

1.  Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex.

Authors:  N A Muma; R K Singh; M S Vercillo; D N D'Souza; B Zemaitaitis; F Garcia; K J Damjanoska; Y Zhang; G Battaglia; L D Van de Kar
Journal:  Neuropharmacology       Date:  2007-07-01       Impact factor: 5.250

2.  Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes.

Authors:  Emilie Lauressergues; Bart Staels; Karine Valeille; Zouher Majd; Dean W Hum; Patrick Duriez; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-24       Impact factor: 3.000

3.  Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.

Authors:  Mikhail Kalinichev; Claire Rourke; Alex J Daniels; Mary K Grizzle; Christy S Britt; Diane M Ignar; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 4.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

6.  Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.

Authors:  Emma Perez-Costas; Paolo Guidetti; Miguel Melendez-Ferro; Joyce J Kelley; Rosalinda C Roberts
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

7.  Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.

Authors:  Guodong Zhang; Alvin V Terry; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-17       Impact factor: 3.205

8.  Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs.

Authors:  L J Hampson; P Mackin; L Agius
Journal:  Diabetologia       Date:  2007-06-20       Impact factor: 10.122

9.  Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions.

Authors:  S Unterecker; P Riederer; F Proft; J Maloney; J Deckert; B Pfuhlmann
Journal:  J Neural Transm (Vienna)       Date:  2012-12-20       Impact factor: 3.575

10.  Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.

Authors:  Nathan L Sparkman; Ming Li
Journal:  Behav Pharmacol       Date:  2012-10       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.